Overall, taking the studies which compared fetuin-A concentrations between patients with NAFLD and the controls, it was found that fetuin-A concentrations were significantly higher in NAFLD patients than in the controls, with high effect (SMD = 0.83, 95% CI: 0.59 to 1.07, p < 0.001), and heterogeneity was considerable (I2 = 91.1%). The gene discussed is AHSG; the disease is metabolic dysfunction-associated steatotic liver disease.